(Total Views: 226)
Posted On: 07/02/2019 1:41:25 PM
Post# of 36566
Joe mentioned Kite Pharma in one of his posts - they also are a CAR-T company. Here is what happened to them:
In June 2014, Kite Pharma sold 8,625,000 shares of its common stock in their IPO at $17.00 per share, for gross proceeds of $146.6 million.[42][43][44] The company listed on the NASDAQ Global market under the symbol “KITE.”
In December 2014, Kite Pharma sold 4,007,750 shares of it common stock in their follow-on offering at $54.00 per share, for gross proceeds of $216.4 million.[45]
In December 2015, Kite Pharma sold 4,168,750 shares of its common stock in a public offering at $69.00 per share, for gross proceeds of $287.6 million.[48]
On August 28, 2017, Gilead Sciences announced that it would purchase Kite Pharma for $11.9 billion in cash ($180.00 per share).[51]
In June 2014, Kite Pharma sold 8,625,000 shares of its common stock in their IPO at $17.00 per share, for gross proceeds of $146.6 million.[42][43][44] The company listed on the NASDAQ Global market under the symbol “KITE.”
In December 2014, Kite Pharma sold 4,007,750 shares of it common stock in their follow-on offering at $54.00 per share, for gross proceeds of $216.4 million.[45]
In December 2015, Kite Pharma sold 4,168,750 shares of its common stock in a public offering at $69.00 per share, for gross proceeds of $287.6 million.[48]
On August 28, 2017, Gilead Sciences announced that it would purchase Kite Pharma for $11.9 billion in cash ($180.00 per share).[51]
(4)
(0)
